LU91501I2 - Sugammadex et ses sels pharmaceutiquement acceptables-BRIDION - Google Patents

Sugammadex et ses sels pharmaceutiquement acceptables-BRIDION

Info

Publication number
LU91501I2
LU91501I2 LU91501C LU91501C LU91501I2 LU 91501 I2 LU91501 I2 LU 91501I2 LU 91501 C LU91501 C LU 91501C LU 91501 C LU91501 C LU 91501C LU 91501 I2 LU91501 I2 LU 91501I2
Authority
LU
Luxembourg
Prior art keywords
bridion
sugammadex
pharmaceutically acceptable
acceptable salts
salts
Prior art date
Application number
LU91501C
Other languages
English (en)
French (fr)
Other versions
LU91501I9 (xx
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8241767&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91501(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Organon Nv filed Critical Organon Nv
Publication of LU91501I2 publication Critical patent/LU91501I2/xx
Publication of LU91501I9 publication Critical patent/LU91501I9/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/724Cyclodextrins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
LU91501C 1999-11-29 2008-11-26 Sugammadex et ses sels pharmaceutiquement acceptables-BRIDION LU91501I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99309558 1999-11-29
PCT/EP2000/011789 WO2001040316A1 (en) 1999-11-29 2000-11-23 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
EP00993261A EP1259550B1 (en) 1999-11-29 2000-11-23 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block

Publications (2)

Publication Number Publication Date
LU91501I2 true LU91501I2 (fr) 2009-01-26
LU91501I9 LU91501I9 (xx) 2019-01-02

Family

ID=8241767

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91501C LU91501I2 (fr) 1999-11-29 2008-11-26 Sugammadex et ses sels pharmaceutiquement acceptables-BRIDION

Country Status (34)

Country Link
US (3) USRE44733E1 (xx)
EP (1) EP1259550B1 (xx)
JP (2) JP3880041B2 (xx)
KR (1) KR100716524B1 (xx)
CN (1) CN1188428C (xx)
AR (1) AR026605A1 (xx)
AT (1) ATE288450T1 (xx)
AU (1) AU776536B2 (xx)
BE (1) BE2008C047I2 (xx)
BR (1) BRPI0015947B8 (xx)
CA (1) CA2390463C (xx)
CO (1) CO5251450A1 (xx)
CY (1) CY2008018I2 (xx)
CZ (1) CZ298206B6 (xx)
DE (2) DE122008000068I2 (xx)
DK (1) DK1259550T3 (xx)
ES (1) ES2237496T3 (xx)
FR (1) FR08C0052I2 (xx)
HK (1) HK1049489A1 (xx)
HU (1) HU227451B1 (xx)
IL (1) IL149423A0 (xx)
LU (1) LU91501I2 (xx)
MX (1) MXPA02004940A (xx)
NL (1) NL300356I2 (xx)
NO (2) NO328790B1 (xx)
NZ (1) NZ518752A (xx)
PE (1) PE20010902A1 (xx)
PL (1) PL203012B1 (xx)
PT (1) PT1259550E (xx)
RU (1) RU2260013C2 (xx)
SK (1) SK286282B6 (xx)
TW (1) TWI242015B (xx)
WO (1) WO2001040316A1 (xx)
ZA (1) ZA200203538B (xx)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6744471B1 (en) * 1997-12-05 2004-06-01 Olympus Optical Co., Ltd Electronic camera that synthesizes two images taken under different exposures
TWI242015B (en) 1999-11-29 2005-10-21 Akzo Nobel Nv 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
EP1629845A3 (en) * 2000-11-02 2006-03-22 Akzo Nobel N.V. Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders
CA2543443A1 (en) 2003-10-31 2005-05-12 The University Of Kansas Sulfoalkyl ether-alkyl ether cyclodextrin derivatives
EP1735326A4 (en) 2004-01-29 2011-04-20 Pinnacle Pharmaceuticals BETA-CYCLODEXTRIN DERIVATIVES AND THEIR USE AGAINST LETHAL TOXIN OF ANTHRAX
SI2708225T1 (sl) 2004-04-23 2019-05-31 Cydex Pharmaceuticals, Inc. Formulacija DPI, ki vsebuje sulfoalkil eter ciklodekstrin
WO2006083678A2 (en) 2005-01-28 2006-08-10 Pinnacle Pharmaceuticals, Inc. β-CYCLODEXTRIN DERIVATIVES AS ANTIBACTERIAL AGENTS
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
PL2335707T3 (pl) 2005-10-26 2015-10-30 Cydex Pharmaceuticals Inc Kompozycje eteru sulfoalkilowego cyklodekstryny i sposoby ich wytwarzania
US20090069412A1 (en) * 2007-09-09 2009-03-12 Protia, Llc Deuterium-enriched sugammadex
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
US7938283B2 (en) * 2008-06-20 2011-05-10 Grainpro, Inc. System and method for hermetic storage of agricultural commodities during shipping
WO2010053487A1 (en) 2008-11-07 2010-05-14 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
CN101591402B (zh) * 2009-05-05 2011-11-30 杭州奥默医药技术有限公司 6-脱氧砜类环糊精衍生物及其制备方法
US8492538B1 (en) 2009-06-04 2013-07-23 Jose R. Matos Cyclodextrin derivative salts
DE102010012281A1 (de) * 2010-03-22 2011-09-22 Fresenius Medical Care Deutschland Gmbh Pharmazeutische Zusammensetzungen enthaltend substituiertes 6-Deoxy-6-sulfanylcyclodextrin
CN101864003B (zh) * 2010-06-11 2012-05-02 漆又毛 一种6-脱氧硫醚氨基酸环糊精衍生物的合成方法
ES2551585T3 (es) * 2010-08-25 2015-11-20 Davuluri, Ramamohan Rao Procedimiento mejorado para la preparación de Sugammadex
CN102060941B (zh) 2010-11-26 2012-12-26 漆又毛 6-脱氧α-氨基酸衍生物环糊精及制备和应用
CN104271605B (zh) 2012-02-15 2017-07-25 锡德克斯药物公司 环糊精衍生物的制造方法
RU2747757C2 (ru) 2012-02-28 2021-05-13 Сидекс Фармасьютикалс, Инк. Композиции алкилированного циклодекстрина и способы их получения и применения
JP5892847B2 (ja) * 2012-04-27 2016-03-23 Dowaホールディングス株式会社 シクロデキストリンとシリカ含有物質との複合材料、及びその製造方法、並びにガス吸着剤
GB201211153D0 (en) * 2012-06-22 2012-08-08 Farmhispania Pharmaceutical compositions
MY181829A (en) 2012-10-22 2021-01-08 Cydex Pharmaceuticals Inc Alkylated cyclodextrin compositions and processes for preparing and using the same
WO2014125501A1 (en) 2013-02-14 2014-08-21 Neuland Laboratories Limited An improved process for preparation of sugammadex sodium
WO2015179963A1 (en) 2014-05-29 2015-12-03 Uti Limited Partnership Cyclodextrin-based polyanionic and non-ionic dendrimers
CN107073007A (zh) 2014-06-26 2017-08-18 丸石制药株式会社 具有改进的稳定性的罗库溴铵制剂
CN105348412B (zh) * 2014-08-22 2018-06-05 江苏恩华药业股份有限公司 一种舒更葡糖钠的纯化方法
JP6914188B2 (ja) 2014-08-22 2021-08-04 サイデックス・ファーマシューティカルズ・インコーポレイテッド 分画アルキル化シクロデキストリン組成物ならびにその調製方法および使用方法
MX2017011966A (es) 2015-03-19 2018-06-06 Cydex Pharmaceuticals Inc Composiciones que contienen silimarina y sulfoalquil eter ciclodextrina y metodos de uso de las mismas.
CN104844732B (zh) * 2015-03-27 2017-05-03 山东滨州智源生物科技有限公司 一种舒更葡糖钠的制备方法
AU2015390471A1 (en) * 2015-04-08 2017-11-09 John KLASSEN Pharmaceutical compositions of polyanionic and non-ionic cyclodextrin-based dendrimers and uses thereof
JP6946275B2 (ja) * 2015-05-29 2021-10-06 ラクシュミ・プラサド・アラパルティLakshmi Prasad ALAPARTHI スガマデクスおよびその中間体の製造方法
CN104922693A (zh) * 2015-06-19 2015-09-23 南开大学 一种阴离子型环糊精与抗癌药物包合物及制备方法
EP3359578A4 (en) * 2015-10-07 2019-05-15 UTI Limited Partnership MULTIFUNCTIONAL POLYANIONIC CYCLODEXTRIN DENDRIMERS
CN108291057B (zh) 2015-11-25 2021-07-13 费森尤斯卡比依普莎姆有限责任公司 全氯代-γ-环糊精的晶体形式
KR102251673B1 (ko) * 2015-11-25 2021-05-13 프레제니우스 카비 입섬 에스. 알. 엘. 슈감마덱스 및 이의 중간체 제조를 위한 개선된 방법
EP3733717A3 (en) 2016-03-22 2020-12-30 Fresenius Kabi iPSUM S.r.l. An improved process for the preparation of sugammadex
PT3448395T (pt) * 2016-04-29 2020-06-01 Alveron Pharma B V Ciclodextrinas como pró-coagulantes
ES2915423T3 (es) 2016-06-23 2022-06-22 Synthon Bv Proceso de preparación de sugammadex
US20180016359A1 (en) * 2016-06-29 2018-01-18 Beijing Creatron Institute Of Pharmaceutical Research Co., Ltd. Sugammadex preparation and purification method
US10526422B2 (en) 2016-06-29 2020-01-07 Beijing Creatron Institute Of Pharmaceutical Research Co., Ltd. Process for preparation and purification of Sugammades sodium
CN107778383B (zh) 2016-08-24 2020-03-10 王炳永 一种舒更葡糖钠的精制方法
US10385142B2 (en) 2017-01-23 2019-08-20 Scinopharm Taiwan, Ltd. Method for preparing sugammadex sodium
US20180318249A1 (en) 2017-05-03 2018-11-08 Cydex Pharmaceuticals, Inc. Composition containing cyclodextrin and busulfan
CN109021148B (zh) * 2017-06-08 2020-11-10 天津科伦药物研究有限公司 一种制备舒更葡糖钠的方法
US10442871B2 (en) * 2017-06-22 2019-10-15 Lawrence Livermore National Security, Llc Modified cyclodextrins for the selective sequestration of fentanyl related compounds and uses thereof
ES2761899T3 (es) 2017-06-30 2020-05-21 Synthon Bv Proceso para preparar Sugammadex
TWI703163B (zh) * 2017-08-23 2020-09-01 台耀化學股份有限公司 舒更葡糖鈉之製備方法及其晶型
US10233263B1 (en) * 2017-08-23 2019-03-19 Formosa Laboratories, Inc. Method for preparation of sugammadex sodium
CN107892727B (zh) * 2017-11-27 2019-12-24 合肥博思科创医药科技有限公司 一种舒更葡糖钠的纯化方法
US11104746B2 (en) 2017-11-27 2021-08-31 Medichem, S.A. Process for the synthesis of a cyclodextrin derivative
EP3775026B1 (en) 2018-04-06 2022-03-16 Synthon B.V. Purification of sugammadex
KR102054228B1 (ko) 2018-05-28 2019-12-10 연성정밀화학(주) 슈가마덱스 나트륨염의 제조방법
MX2020013117A (es) * 2018-06-07 2021-02-18 Merck Sharp & Dohme Llc Procesos para la preparacion de sugammadex.
CN110615860A (zh) * 2018-06-20 2019-12-27 江苏恒瑞医药股份有限公司 一种舒更葡糖钠的纯化方法
EP3830184A1 (en) 2018-08-02 2021-06-09 Pliva Hrvatska D.O.O. Solid state forms of sugammadex sodium
US11845811B2 (en) 2018-09-20 2023-12-19 Natco Pharma Limited Process for the preparation of Sugammadex sodium and its novel polymorphic form
CA3112872A1 (en) 2018-09-27 2020-04-02 Werthenstein Biopharma Gmbh Novel crystalline forms of sugammadex
JP6950966B2 (ja) * 2018-11-01 2021-10-13 丸石製薬株式会社 スガマデクス又はその薬理学的に許容される塩含有液剤及びその製造方法
CN109438591B (zh) * 2018-12-29 2021-02-09 博瑞生物医药(苏州)股份有限公司 舒更葡糖钠的制备工艺
CN109824800A (zh) * 2018-12-29 2019-05-31 鼎元(天津)生物医药科技有限公司 一种选择性肌松拮抗药舒更葡萄糖钠的制备方法
US20220169753A1 (en) 2019-03-29 2022-06-02 Hospira, Inc. An improved process for preparation of sugammadex acid and sugammadex sodium
CN111978435B (zh) 2019-05-22 2021-05-25 合肥博思科创医药科技有限公司 一种高纯度舒更葡糖钠的制备方法
US11324692B2 (en) 2019-07-03 2022-05-10 Galenicum Health S.L.U. Method to prepare pharmaceutical compositions of suggamadex
US20220273517A1 (en) 2019-08-30 2022-09-01 Terumo Kabushiki Kaisha Injection formulation
RU2724900C1 (ru) * 2019-10-24 2020-06-26 Маруиси Фармасьютикал Ко., Лтд. Препарат рокурония с улучшенной стабильностью
CN111019016B (zh) * 2019-12-27 2022-02-18 武汉嘉诺康医药技术有限公司 一种舒更葡糖钠杂质的合成方法
US20230167203A1 (en) 2020-02-28 2023-06-01 Medichem, S.A. Method for drying sugammadex
CN111714459B (zh) * 2020-06-18 2022-06-14 广州瑞尔医药科技有限公司 一种注射用舒更葡糖钠粉针剂及其制备方法
US11097023B1 (en) 2020-07-02 2021-08-24 Par Pharmaceutical, Inc. Pre-filled syringe containing sugammadex
EP3932391A1 (en) 2020-07-03 2022-01-05 Galenicum Health S.L.U. Method to prepare pharmaceutical compositions
US11446325B2 (en) * 2020-09-30 2022-09-20 Cyclolab Cyclodextrin Research And Development Laboratory Ltd. Cyclodextrin derivatives in the treatment or prevention of lysosomal neurodegenerative diseases
US11945788B2 (en) 2021-06-07 2024-04-02 Nuray Chemicals Private Limited Process for preparing pitolisant hydrochloride and solid-state forms thereof
CN113637097A (zh) * 2021-08-10 2021-11-12 北京恒创星远医药科技有限公司 6-全脱氧-6-全碘代-γ-环糊精晶体及其制备方法和应用
CN115708777A (zh) 2021-08-19 2023-02-24 北京费森尤斯卡比医药有限公司 包含巯基环糊精衍生物或其可药用盐的包装药品和保存方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929813A (en) 1973-12-26 1975-12-30 Interx Research Corp Novel pro-drug derivatives of pyridinium aldoxime type cholinesterase reactivators and process for preparing same
JPS52108027A (en) 1976-03-09 1977-09-10 Rikagaku Kenkyusho Anticarcinogen
US4816462A (en) 1982-05-18 1989-03-28 Nowicky Wassili Method for diagnosing and for the therapeutic treatment of tumors and/or infectious diseases of different types with alkaloid-compounds
HU194858B (en) 1982-12-03 1988-03-28 Chinoin Gyogyszer Es Vegyeszet Process for producing dibenzo/b,d/pirane derivatives and pharmaceutical compositions containing them
IT1196033B (it) 1984-02-22 1988-11-10 Chiesi Farma Spa Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
GB8506792D0 (en) 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
GB8613688D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
JPH0819004B2 (ja) 1986-12-26 1996-02-28 日清製粉株式会社 徐放性医薬製剤
HU201783B (en) 1987-10-13 1990-12-28 Chinoin Gyogyszer Es Vegyeszet Process for producing partially methylized carboxy-acyl-beta-cyclodextrines and salts
US5017566A (en) 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5173481A (en) 1989-04-03 1992-12-22 The United States Of America As Represented By The Department Of Health And Human Services Preparation of specifically substituted cyclodextrins
DK0465535T3 (da) 1989-04-03 1999-03-01 Janssen Pharmaceutica Nv Regioselektive substitutioner i cyclodextriner
EP0447171B1 (en) * 1990-03-15 1994-11-02 Tanabe Seiyaku Co., Ltd. Polysulfate of cyclodextrin derivative and process for preparing the same
US5180716A (en) * 1990-08-01 1993-01-19 The Regents Of The University Of California Cyclodextrin complexes for neuraxial administration of drugs
JP2556236B2 (ja) 1991-08-29 1996-11-20 田辺製薬株式会社 β−シクロデキストリン誘導体のポリ硫酸エステル及びその製法
US5840881A (en) 1992-11-27 1998-11-24 Takeda Chemical Industries, Ltd. Composition containing a water-insoluble or slightly water-soluble compound with enhanced water-solubility
US5767112A (en) 1994-10-21 1998-06-16 Poli Industria Chimica, S.P.A. Muscle relaxant pharmaceutical compositions
AU708107B2 (en) 1994-11-04 1999-07-29 Commonwealth Scientific And Industrial Research Organisation Method for treating animals
GB2307176A (en) * 1995-11-15 1997-05-21 Todd Selwyn Everest Anti-inflammatory clathrating agents for topical use
US5935941A (en) 1997-10-24 1999-08-10 Pitha; Josef Alkylations of cyclodextrins leading to derivatives which have a ridgidly extended cavity
US5834446A (en) * 1996-06-21 1998-11-10 Queen's University At Kingston Nerve process growth modulators
JP4249282B2 (ja) 1998-02-27 2009-04-02 日本食品化工株式会社 新規シクロデキストリン誘導体及びその製造方法
DE69942317D1 (de) 1998-05-29 2010-06-10 Neurosciences Res Found Schmerzlinderung mit anandamide
WO2001012202A2 (en) 1999-08-13 2001-02-22 Akzo Nobel N.V. Use of chemical chelators as reversal agents for drug-induced neuromuscular block
TWI242015B (en) 1999-11-29 2005-10-21 Akzo Nobel Nv 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
US20020111377A1 (en) 2000-12-22 2002-08-15 Albany College Of Pharmacy Transdermal delivery of cannabinoids
WO2002064635A1 (en) 2001-02-14 2002-08-22 Akzo Nobel N.V. 2-alkylated-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
TW200402417A (en) 2002-06-21 2004-02-16 Akzo Nobel Nv 1-[(Indol-3-yl)carbonyl]piperazine derivatives

Also Published As

Publication number Publication date
KR100716524B1 (ko) 2007-05-10
BRPI0015947A (pt) 2002-08-20
AU776536B2 (en) 2004-09-16
EP1259550A1 (en) 2002-11-27
DK1259550T3 (da) 2005-04-25
US6949527B2 (en) 2005-09-27
AU5438001A (en) 2001-06-12
SK286282B6 (sk) 2008-06-06
US20040029833A1 (en) 2004-02-12
PL356097A1 (en) 2004-06-14
CZ20021814A3 (cs) 2002-08-14
NO328790B1 (no) 2010-05-18
US6670340B1 (en) 2003-12-30
HUP0203755A3 (en) 2003-10-28
CZ298206B6 (cs) 2007-07-18
TWI242015B (en) 2005-10-21
BE2008C047I2 (xx) 2019-12-11
MXPA02004940A (es) 2003-05-23
PE20010902A1 (es) 2001-09-06
JP2006348301A (ja) 2006-12-28
HUP0203755A2 (hu) 2003-04-28
JP2003515623A (ja) 2003-05-07
DE122008000068I1 (de) 2009-04-23
LU91501I9 (xx) 2019-01-02
WO2001040316A1 (en) 2001-06-07
BRPI0015947B8 (pt) 2021-07-06
DE122008000068I2 (de) 2011-06-16
DE60017947T2 (de) 2005-06-23
JP4563972B2 (ja) 2010-10-20
NZ518752A (en) 2003-03-28
CO5251450A1 (es) 2003-02-28
HK1049489A1 (en) 2003-05-16
CY2008018I1 (el) 2009-11-04
USRE44733E1 (en) 2014-01-28
CA2390463A1 (en) 2001-06-07
CA2390463C (en) 2009-02-03
PT1259550E (pt) 2005-05-31
BRPI0015947B1 (pt) 2012-02-07
ATE288450T1 (de) 2005-02-15
FR08C0052I1 (xx) 2009-02-27
NO20022522L (no) 2002-05-28
PL203012B1 (pl) 2009-08-31
FR08C0052I2 (fr) 2009-12-18
HU227451B1 (en) 2011-06-28
JP3880041B2 (ja) 2007-02-14
NO20022522D0 (no) 2002-05-28
AR026605A1 (es) 2003-02-19
NO2010019I1 (no) 2010-11-22
CY2008018I2 (el) 2009-11-04
SK7262002A3 (en) 2002-11-06
DE60017947D1 (de) 2005-03-10
EP1259550B1 (en) 2005-02-02
NL300356I1 (nl) 2008-10-01
NL300356I2 (nl) 2009-04-01
ES2237496T3 (es) 2005-08-01
IL149423A0 (en) 2002-11-10
KR20020063900A (ko) 2002-08-05
RU2260013C2 (ru) 2005-09-10
ZA200203538B (en) 2003-08-04
CN1402737A (zh) 2003-03-12
NO2010019I2 (no) 2012-08-27
CN1188428C (zh) 2005-02-09

Similar Documents

Publication Publication Date Title
LU91501I2 (fr) Sugammadex et ses sels pharmaceutiquement acceptables-BRIDION
LU91785I2 (fr) Rapiscan - régadénoson et ses sels.
LU91363I2 (fr) Méthoxy polyéthylène glycol-époétine bêta et ses sels pharmaceutiquement acceptables (MIRCERA)
LU92681I2 (fr) Nintédanib, ses tautomères et ses sels, en particulier Nintédanib et ses sels pharmaceutiquement acceptables, en particulier Nintédanib Esilate
IS6385A (is) Ný notkun og nýjar N-asabísýkló-amíð afleiður
LU91280I2 (fr) Sorafenib et des sels pharmaceutiquement acceptables
NO2008001I1 (no) Vildagliptin og farmasoytisk akseptable salter derav
NO20014560D0 (no) Quinasoliner og terapautisk anvendelse derav
EE200000438A (et) Farmatseutiliselt aktiivne morfolinool
PL350039A1 (en) Transparent acoustical and mechanical barrier
IS6411A (is) Kaspasa tálmar og notkun þeirra
LU91291I2 (fr) Deferasirox et ses sels pharmaceutiquement acceptables (EXJADEr)
NO2005007I1 (no) Pemetrexed og farmasoytisk akseptable salter derav
NO20021400D0 (no) Terapeutiske konazolinderivater
DE50007846D1 (de) Dreschkorb
DE60034639D1 (de) Saug- und Spülvorrichtung
DE50010609D1 (de) Sport-trainings-vorrichtung sowie sport-trainings-system
FI20012462A (fi) Farmaseuttisia formulaatioita ja menetelmiä käsittäen intranasaalista morfiinia
LU91345I2 (fr) Rufinamide et ses sels pharmaceutiquement acceptables (inovelon)
DK1208015T3 (da) Lagerindretning
PT1210085E (pt) Solucoes farmaceuticas de levosimendano
NO20022606D0 (no) Farmasöytiske kombinasjoner
DE60032510D1 (de) Kondom
DE60028486D1 (de) Videocoder und -decoder
DE60032898D1 (de) Arylthiazolidindion- und aryloxazolidinderivate